Adenosine, N-[6-[[4-[5-amino-4-benzoyl-3-[3-(trifluoromethyl)phenyl]-2-thienyl]benzoyl]amino]hexyl]-

Adenosine, N-[6-[[4-[5-amino-4-benzoyl-3-[3-(trifluoromethyl)phenyl]-2-thienyl]benzoyl]amino]hexyl]- Suppliers list
Company Name: TargetMol Chemicals Inc.  
Tel: 15002134094
Email: marketing@targetmol.cn
Company Name: TargetMol Chemicals Inc.  
Tel: 13564774135
Email: marketing@targetmol.com

Adenosine, N-[6-[[4-[5-amino-4-benzoyl-3-[3-(trifluoromethyl)phenyl]-2-thienyl]benzoyl]amino]hexyl]- manufacturers

  • VCP746
  • VCP746 pictures
  • $1520.00
  • 2026-04-20
  • CAS:1582751-84-5
  • Purity:
  • Supply Ability: 10g
Adenosine, N-[6-[[4-[5-amino-4-benzoyl-3-[3-(trifluoromethyl)phenyl]-2-thienyl]benzoyl]amino]hexyl]- Basic information
Product Name:Adenosine, N-[6-[[4-[5-amino-4-benzoyl-3-[3-(trifluoromethyl)phenyl]-2-thienyl]benzoyl]amino]hexyl]-
Synonyms:Adenosine, N-[6-[[4-[5-amino-4-benzoyl-3-[3-(trifluoromethyl)phenyl]-2-thienyl]benzoyl]amino]hexyl]-;VCP746
CAS:1582751-84-5
MF:C41H40F3N7O6S
MW:815.86
EINECS:
Product Categories:
Mol File:1582751-84-5.mol
Adenosine, N-[6-[[4-[5-amino-4-benzoyl-3-[3-(trifluoromethyl)phenyl]-2-thienyl]benzoyl]amino]hexyl]- Structure
Adenosine, N-[6-[[4-[5-amino-4-benzoyl-3-[3-(trifluoromethyl)phenyl]-2-thienyl]benzoyl]amino]hexyl]- Chemical Properties
density 1.50±0.1 g/cm3(Predicted)
storage temp. 2-8°C
solubility DMSO: 2mg/mL, clear
pka13.12±0.70(Predicted)
form powder
color white to beige
InChIKeyXLCQNEBOQXQNGA-IYRWRCLLSA-N
SMILESO=C(C1=CC=C(C=C1)C2=C(C(C(C3=CC=CC=C3)=O)=C(S2)N)C4=CC=CC(C(F)(F)F)=C4)NCCCCCCNC5=C6N=CN(C6=NC=N5)[C@@H]7O[C@@H]([C@H]([C@H]7O)O)CO
Safety Information
WGK Germany WGK 3
Storage Class11 - Combustible Solids
MSDS Information
Adenosine, N-[6-[[4-[5-amino-4-benzoyl-3-[3-(trifluoromethyl)phenyl]-2-thienyl]benzoyl]amino]hexyl]- Usage And Synthesis
Biological ActivityVCP746 is an adenosine receptor A1 (A1AR) agonist composed of adenosine linked to the A1AR positive allosteric modulator VCP171, allowing greatly improved affinity (KI = 58.9 nM vs. 2.95 μM/adenosine & 1.55 μM/VCP171) and potency (GTPγS binding induction EC50 = 0.89 nM vs. 93.3 nM/adenosine & 977 nM/VCP171; hA1AR-CHO membrane) via bitopic receptor engagement with both orthosteric and allosteric sites, as well as biased agonism toward inhibition of forskolin-stimulated cAMP over ERK1/2 phosphorylation (hA1AR-CHO) without hA3AR agonist potency. VCP746 protects against ischemia/hypoxia-induced death of r at neonatal ventricular cardiomyocytes (1 μM) and embryonic cardiomyoblasts (300 nM) without affecting isolated r at atrial heart rate.
Adenosine, N-[6-[[4-[5-amino-4-benzoyl-3-[3-(trifluoromethyl)phenyl]-2-thienyl]benzoyl]amino]hexyl]- Preparation Products And Raw materials
Tag:Adenosine, N-[6-[[4-[5-amino-4-benzoyl-3-[3-(trifluoromethyl)phenyl]-2-thienyl]benzoyl]amino]hexyl]-(1582751-84-5) Related Product Information